Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Solutions

    Solutions

    Our solutions span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Solutions
    Clinical & Scientific OperationsConsultingEarly ClinicalLaboratoriesLanguage ServicesMedical ImagingSite & Patient Solutions Strategic SolutionsSymphony Health Technologies
    End-to-end services, operational model and technology to deliver customised solutions.
    Decentralised Clinical Trial Solutions

    End-to-end services, operational model and technology to deliver customised solutions.

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
    Real World Intelligence®

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment and Public HealthMedical DevicePharmaceuticals
    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    18 September 2023
    Webinar: Perinatal Mood Disorders

    18 September 2023

    26 September 2023
    Webinar: Financial Times - Decentralised Clinical Trials in Focus

    26 September 2023

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyHealthcare IntelligenceICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Clinical Research. Evolved.
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. In the News
  4. How real world evidence is impacting rare disease drug development

How real world evidence is impacting rare disease drug development

Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.

Read article
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
      • BioEquity Europe
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

Related information

Webpage

Rare & Orphan Diseases

Webpage

Insights: Rare & Orphan Diseases

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy & Data
  • Site Cookies

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media